Tumours are helped in their development by mutating the most important cancer-prevention gene, p53, scientists from Melbourne have found. The study, published in Genes and Development, found that mutant p53 prevents the regular p53 protein from activating its natural defences, increasing the risk of the cancer spreading.
Oncology is the most advanced area in genomics right now. The field is setting the standard for other indications to follow and improve upon.
Scientists from Cancer Research UK in Cambridge have advanced research into liquid biopsies for brain tumours by detecting tumour DNA in the fluid around the spine and brain.
If you’ve been part of the GeoMx DSP Technology Access Program, then you’ll already know why this is so exciting. If you haven’t heard about it yet, then you should make sure you’re sitting down – yes it really is that exciting.
AMP 2018: Decoding the Cancer Genome: Breakthrough AI Technology Quickly Identifies Actionable Mutations
Explosive advances in next-generation sequencing (NGS) have greatly improved the ability to identify actionable cancer mutations, both for solid and hematological malignancies, and sparked a new era of oncology care. But accurate analysis and proper interpretation of the complex genomic data produced by NGS remain key hurdles.
Cells settling in an organ other than the correct one during embryogenesis are often the cause of rare ovarian and pancreatic cancers which affect only young women, researchers at the University of Geneva (UNIGE) and the University Hospitals of Geneva (HUG) have found.
Genomics England names Congenica as its Clinical Decision Support Service partner for the delivery of the NHS Genomic Medicine Service.
A new scientific innovation is set to help scientists understand the causes of cancer with greater speed and precision than ever before. Rather than looking at individual gene mutations on their own, scientists can now create models incorporating a number of mutations.
The 2018 Nobel Prize for Physiology or Medicine has been awarded to James Allison and Tasuku Honjo for their work on cancer immunotherapy.
ASCO checkpoint inhibitor battle between Merck and Roche highlights the pitfalls in directly comparing clinical trial results in the era of precision medicine.
With artificial intelligence, machines can now examine thousands of medical images for signs of disease. Will this technology replace doctors – or work side by side with them?
Scientists have long thought that regions of DNA called telomeres control how long you live. We are now learning that it is your diet and lifestyle that shape your telomeres, not the other way around.
A team of tiny molecules that work together to make cancer cells less aggressive has been discovered by Australian researchers.
Researchers at the Weizmann Institute of Science, in collaboration with physicians, have conducted a study in mice, in which they used existing drugs in a new combination to help crush potential resistance to treatment.